# Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

> **NCT03732274** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedPacto, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** TEW-7197

## Key facts

- **NCT ID:** NCT03732274
- **Lead sponsor:** MedPacto, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-11
- **Primary completion:** 2024-05-17
- **Final completion:** 2024-05-17
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732274, "Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03732274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*